Imhoff John E

Imhoff John E has demonstrated a consistent buying bias in their trading activity, with no recorded sales across 28 transactions totaling approximately $2.89 million in purchases. All activity has been concentrated in Guidant Therapeutics Holdings (GTHP), with recent acquisitions continuing this pattern. On February 27, 2026, Imhoff acquired $10,926 worth of GTHP shares, following a $21,890 purchase earlier that month and a $13,682 buy in December 2025. These smaller transactions contrast with earlier, larger investments, including a $300,000 private placement in August 2025 and a $100,000 purchase alongside a $263,069 transaction in March 2025. The filings show a mix of open-market purchases (code C) and private placements (code P), with the latter accounting for the bulk of the investment value. Notably, a March 2025 filing reported a $2.4 million acquisition through a derivative transaction (code J), though subsequent filings clarified this as a non-monetary adjustment. Imhoff’s sustained accumulation of GTHP shares—without any dispositions—suggests a long-term position in the company, reinforced by continued buying as recently as February 2026. The absence of sales, even after substantial holdings were established, indicates a persistent bullish stance.